Herpes Zoster - A Pipeline Analysis Report

This pipeline analysis report provides detailed insights into the clinical trials landscape of the drug development for herpes zoster including molecules at pre-clinical and discovery stage. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentation such as therapy, route of administration, and target.

Overview of the drug development pipeline for herpes zoster

Herpes zoster, which is also known as shingles, is a viral infection caused by the varicella-zoster virus. Varicella-zoster virus is also responsible for causing chicken pox infection. Even after the chicken pox is cured, the virus remains in the nervous system and gets activated to cause herpes zoster. The common symptoms of herpes zoster are the development of red rashes around the rib cage or waist, which causes pain and burning sensation. The infection appears in the form of blisters present in a strip fashion on one side of the body. Blisters usually occur on the torso, neck, or face. Older adults who typically have a weakened immune system are more susceptible to herpes zoster infection. According to the CDC, in the US, 99.5% of the people aged above 40 years are prone to be infected by the herpes zoster virus. The most efficient approach for the treatment of herpes zoster infection is emerging to be monotherapy.

According to this pipeline analysis report, all the drug molecules in the pipeline are being developed for herpes zoster. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Drug development pipeline report for herpes zoster: Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of herpes zoster. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are

• Bausch & Lomb
• ContraVir Pharmaceuticals
• EMS Pharma

Therapeutic assessment of the drug development pipeline for herpes zoster by route of administration

• Oral
• Subcutaneous
• Intramuscular
• Topical
• Unknown

The oral route of administration (ROA) involves the application of the drug directly into the mouth cavity and in the subcutaneous technique, the molecules are delivered directly into the layer of the skin below the dermis and the epidermis, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development pipeline for herpes zoster by therapy

• Monotherapy
• Monotherapy/Combination therapy

According to this pipeline analysis report, most of the molecules that are currently in the drug pipeline for herpes zoster are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the gene therapy molecules in the various development stages for herpes zoster?
• What are the companies that are currently involved in the development of drug molecules for herpes zoster?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.